Relapsed or Refractory Hematologic Malignancies
6
3
3
1
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 6 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 1 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (6)
Safety and Efficacy of DIT101 in Relapsed or Refractory Hematologic Malignancies
Tolerability Study of Trichostatin A In Subjects With Relapsed or Refractory Hematologic Malignancies
Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia Safety and Efficacy of Venetoclax With Escalating Doses of Omacetaxine in Patients With Acute Myeloid Leukemia (AML)
A Phase I Study of QLS2309 Injection in Patients With CD70+ Relapsed/Refractory Hematologic Malignancies
A Clinical Study of BT02 in Patients With Relapsed or Refractory Hematologic Malignancies
A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies